Anchorage Capital Advisors, L.P. - 28 Jun 2024 Form 3 Insider Report for Cano Health, Inc.

Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
08 Jul 2024, 16:13:19 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
Anchorage Capital Advisors, L.P., By: /s/ Robert Dunleavy, Chief Operating Officer

Key filing fact

Anchorage Capital Advisors, L.P. filed Form 3 for Cano Health, Inc. on 08 Jul 2024.

Key facts

  • This page summarizes Anchorage Capital Advisors, L.P.'s Form 3 filing for Cano Health, Inc..
  • 0 reported transactions and 3 derivative rows are listed below.
  • Accepted by SEC: 08 Jul 2024, 16:13.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CANO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
4,144,418
Date
28 Jun 2024
Ownership
See Footnote
Footnotes
F1, F4
CANO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
613,129
Date
28 Jun 2024
Ownership
See Footnote
Footnotes
F2, F4
CANO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
120,261
Date
28 Jun 2024
Ownership
See Footnote
Footnotes
F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CANO holding Derivative

Warrants (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
28 Jun 2024
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
128,581
Exercise price
$25.30
Footnotes
F1, F4, F5, F6
CANO holding Derivative

Warrants (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
28 Jun 2024
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
18,659
Exercise price
$25.30
Footnotes
F2, F4, F5, F6
CANO holding Derivative

Warrants (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
28 Jun 2024
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
3,842
Exercise price
$25.30
Footnotes
F3, F4, F5, F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

These securities are held for the accounts of funds managed by Anchorage Collateral Management, L.L.C., a relying adviser of Anchorage Capital Advisors, L.P. ("Capital Advisors"), its sole member.

Footnote F2

These securities are held for the account of a fund managed by Anchorage Opportunities Advisor, L.L.C., a relying adviser of Capital Advisors, its sole member.

Footnote F3

These securities are held for the accounts of funds managed by Anchorage Strategies Advisor, L.L.C., a relying adviser of Capital Advisors, its sole member.

Footnote F4

Anchorage Advisor Holdings Management, L.P. ("Holdings Management") is the majority owner of Capital Advisors. Anchorage Advisor Holdings GP, L.L.C. ("Holdings GP") is the sole general partner of each of Capital Advisors and Holdings Management. Mr. Baron and Mr. Gournay are co-managing members of Holdings GP. Each of Capital Advisors, Holdings Management, Holdings GP, Mr. Baron and Mr. Gournay may therefore be deemed to beneficially own the securities reported herein, and each disclaims beneficial ownership of the reported securities except to the extent, if any, of its or his pecuniary interest therein, and this report shall not be deemed an admission that it or he is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Footnote F5

These warrants will expire on June 28, 2029, or earlier upon the occurrence of certain events as set forth in the related warrant agreement (the "Warrant Agreement").

Footnote F6

These warrants have an initial exercise price of $25.30 per share of Common Stock, subject to certain customary adjustments as set forth in the Warrant Agreement.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .